Resultados de procura - Lisa Lundgren

  • Mostrando 1 - 7 Resultados de 7
Limitar resultados
  1. 1
    Securing tomorrow’s workforce: insights from a Danish survey on factors influencing junior doctors’ specialization in geriatric medicine

    Securing tomorrow’s workforce: insights from a Danish survey on factors influencing junior doctors’ specialization in geriatric medicine por Lene Holst Andersen, Eva‐Lisa Lundgren, Pernille Holm Ellegaard, Siri Aas Smedemark, Karen Andersen‐Ranberg

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Leveraging Citizen Science in a College Classroom to Build Interest and Efficacy for Science and the Environment

    Leveraging Citizen Science in a College Classroom to Build Interest and Efficacy for Science and the Environment por Haley E. Smith, Bradley C. Allf, Lincoln R. Larson, Sara Futch, Lisa Lundgren, Lara B. Pacifici, Caren B. Cooper

    Publicado 2021
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Tuberculosis following PD-1 blockade for cancer immunotherapy

    Tuberculosis following PD-1 blockade for cancer immunotherapy por Daniel L. Barber, Shunsuke Sakai, Ragini R. Kudchadkar, Steven P. Fling, Tracey A. Day, Julie Vergara, David Ashkin, Jonathan Cheng, Lisa Lundgren, Vanessa Raabe, Colleen S. Kraft, Jorge J. Nieva, Martin A. Cheever, Paul Nghiem, Elad Sharon

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

    Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study por Thomas S. Uldrick, Priscila Gonçalves, Maher Abdul‐Hay, Alisa J Claeys, Brinda Emu, Marc S. Ernstoff, Steven P. Fling, Lawrence Fong, Judith C. Kaiser, Andreanne M. Lacroix, Steve Y. Lee, Lisa Lundgren, Kathryn Lurain, Christopher Parsons, Sharavi Peeramsetti, Ramya Ramaswami, Elad Sharon, Mario Sznol, Chia-Ching Wang, Robert Yarchoan, Martin A. Cheever

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

    Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab por Nicolás A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul Nghiem, Suzanne L. Topalian, Janis M. Taube

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

    PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma por Paul Nghiem, Shailender Bhatia, Evan J. Lipson, Ragini R. Kudchadkar, Natalie Miller, Lakshmanan Annamalai, Sneha Berry, Elliot Chartash, Adil Daud, Steven P. Fling, Philip Friedlander, Harriet M. Kluger, Holbrook E. Kohrt, Lisa Lundgren, Kim Margolin, Alan Mitchell, Thomas Olencki, Drew M. Pardoll, Sunil Reddy, Erica Shantha, William H. Sharfman, Elad Sharon, Lynn Shemanski, Michi M. Shinohara, Joel Sunshine, Janis M. Taube, John A. Thompson, Steven M. Townson, Jennifer H. Yearley, Suzanne L. Topalian, Martin A. Cheever

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

    Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy por Paul Nghiem, Shailender Bhatia, Evan J. Lipson, William H. Sharfman, Ragini R. Kudchadkar, Andrew S. Brohl, Phillip Friedlander, Adil Daud, Harriet M. Kluger, Sunil Reddy, Brian C. Boulmay, Adam I. Riker, Melissa Burgess, Brent A. Hanks, Thomas Olencki, Kim Margolin, Lisa Lundgren, Abha Soni, Nirasha Ramchurren, Candice D. Church, Song Y. Park, Michi M. Shinohara, Bob Salim, Janis M. Taube, Steven Bird, Nageatte Ibrahim, Steven P. Fling, Blanca Homet Moreno, Elad Sharon, Martin A. Cheever, Suzanne L. Topalian

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: